Biosimilar Antibodies
Biosimilar antibodies are copies of therapeutic antibodies with highly similar quality and efficacy that have been approved for medical use. Research-grade biosimilar antibodies offer a more readily available and cost effective alternative to the original antibody. and can serve as a reference antibody in the development of new biologics. Assay genie provides a range of high grade biosimilar antibodies produced under strict quality control processes to enable fast and cost effective research.
Features & Benefits
- Research grade (RUO) biosimilar antibodies
- Purified from cell supernatant by affinity chromatography
- Antibodies are validated for target binding verification and off target effects by ELISA and flow cytometry to ensure quality and specificity
- Demonstrated to be low or non-immunogenic
Applications
- Ligand binding assays
- Biologics development
- Use as a reference antibody in pipeline drug development
- In vivo Animal studies
- Reference antibody in ELISA and flow cytometry
- Studying of biochemical pathways
Biosimilar Antibodies
| Product name | Reactivity | Host | Clonality | Application |
| Anti-4-1BB (Utomilumab) Antibody | Human | Homo sapiens | Monoclonal | ELISA |
| Anti-AXL (Enapotamab) Antibody | Human | Homo sapiens | Monoclonal | ELISA, Flow Cyt |
| Anti-B7-H3 (Enoblituzumab) Antibody | Human | Humanized | Monoclonal | ELISA, Flow Cyt |
| Anti-BAFF (Belimumab) Antibody | Human | Homo sapiens | Monoclonal | ELISA |
| Anti-BAFFR (Ianalumab) Antibody | Human | Homo sapiens | Monoclonal | ELISA, Flow Cyt |
| Anti-BCMA Antibody | Human | Humanized | Monoclonal | ELISA |
| Anti-BCMA (Belantamab) Antibody | Human | Humanized | Monoclonal | ELISA |
| Anti-CA9 (Girentuximab) Antibody | Human | Chimeric | Monoclonal | ELISA, Flow Cyt |
| Anti-CD123 (Talacotuzumab) Antibody | Human | Humanized | Monoclonal | ELISA, Flow Cyt |
| Anti-CD138 (Indatuximab ravtansine) Antibody | Human | Chimeric | Monoclonal | Flow Cyt |
| Anti-CD20 (Rituximab) Antibody | Human | Chimeric | Monoclonal | Flow Cyt |
| Anti-CD22 (Pinatuzumab) Antibody | Human | Humanized | Monoclonal | ELISA, Flow Cyt |
| Anti-CD27 (Varlilumab) Antibody | Human | Homo sapiens | Monoclonal | ELISA |
| Anti-CD30 (Brentuximab vedotin) Antibody | Human | Chimeric | Monoclonal | ELISA |
| Anti-CD33 (Gemtuzumab ozogamicin) Antibody | Human | Humanized | Monoclonal | Flow Cyt |
| Anti-CD37 (Naratuximab) Antibody | Human | Chimeric | Monoclonal | Flow Cyt |
| Anti-CD38 (Daratumumab) Antibody | Human | Homo sapiens | Monoclonal | ELISA, Flow Cyt |
| Anti-CD40 (Iscalimab)Antibody | Human | Homo sapiens | Monoclonal | ELISA |
| Anti-CD40L (Ruplizumab) Antibody | Human | Humanized | Monoclonal | ELISA, Flow Cyt |
| Anti-CD47 (Magrolimab) Antibody | Human | Homo sapiens | Monoclonal | ELISA, Flow Cyt |
| Anti-CD52 (Alemtuzumab) Antibody | Human | Humanized | Monoclonal | Flow Cyt |
| Anti-CD70 (Vorsetuzumab) Antibody | Human | Homo sapiens | Monoclonal | ELISA, Flow Cyt |
| Anti-CEACAM5 (Labetuzumab) Antibody | Human | Humanized | Monoclonal | ELISA |
| Anti-CS1 (Elotuzumab) Antibody | Human | Humanized | Monoclonal | ELISA, Flow Cyt |
| Anti-CTLA4 (Ipilimumab) Antibody | Human | Homo sapiens | Monoclonal | ELISA |
| Anti-EGFR (Cetuximab biosimilar) Antibody | Human | Chimeric | Monoclonal | ELISA |
| Anti-EPHA3 (Ifabotuzumab) Antibody | Human | Humanized | Monoclonal | ELISA |
| Anti-ICAM1 (Bersanlimab) Antibody | Human | Homo sapiens | Monoclonal | ELISA |
| Anti-ICOS (Vopratelimab) Antibody | Human | Humanized | Monoclonal | ELISA, Flow Cyt |
| Anti-IL17RA (Brodalumab) Antibody | Human | Homo sapiens | Monoclonal | ELISA, Flow Cyt |
| Anti-IL2RA (Basiliximab) Antibody | Human | Chimeric | Monoclonal | ELISA, Flow Cyt |
| Anti-IL6 (Siltuximab) Antibody | Human | Chimeric | Monoclonal | ELISA, Flow Cyt |
| Anti-IL6R (Tocilizumab) Antibody | Human | Humanized | Monoclonal | ELISA, Flow Cyt |
| Anti-Mesothelin (Amatuximab) Antibody | Human | Chimeric | Monoclonal | ELISA |
| Anti-NKG2D (Tesnatilimab) Antibody | Human | Homo sapiens | Monoclonal | ELISA |
| Anti-PD-1 (Pembrolizumab) Antibody | Human | Humanized | Monoclonal | ELISA, Flow Cyt |
| Anti-PDL1 (Atezolizumab) Antibody | Human | Humanized | Monoclonal | ELISA, Flow Cyt |
| Anti-TIGIT (Etigilimab) Antibody | Human | Humanized | Monoclonal | ELISA |
| Anti-TIGIT (Tiragolumab) Antibody | Human | Homo sapiens | Monoclonal | ELISA |
| Anti-TIGIT (Vibostolimab) Antibody | Human | Humanized | Monoclonal | ELISA |
| Anti-TIM3 (Cobolimab) Antibody | Human | Humanized | Monoclonal | ELISA, Flow Cyt |
| Anti-TNFRSF10B (Tigatuzumab) Antibody | Human | Humanized | Monoclonal | ELISA |
| Anti-Trop2 (Sacituzumab govitecan) Antibody | Human | Humanized | Monoclonal | ELISA |
| Anti-TweakR (Enavatuzumab) Antibody | Human | Humanized | Monoclonal | ELISA |
Technology
Assay Genie’s biosimilar antibodies are produced using a revolutionary high throughput technology for monoclonal antibody development. Unlike hybridoma based monoclonal antibodies, this new technology can obtain IgG sequences from immunoreactive B cells directly with no need for hybridoma fusion. With no need for a hybridoma fusion, it will soon be possible to raise monoclonal antibodies from a range of animal species. Over 1000 immunoreactive B cells can be isolated from a single animal. Such high numbers means greater success in obtaining monoclonal antibodies with higher specificity, sensitivity and affinity. Directly obtaining the IgG sequences also means direct editing and optimisation of antibodies is possible for humanization.
Quality Control Data
Figure 1: ELISA plate precoated with 2 µg/ml Human CD47. Anti-CD47 (Magrolimab) biosimilar binds to Human CD47 and can be detected in a range of 0.061-1.606 ng/ml using a mFc-His tagged protein
Figure 2: HEK293 cells transfected with (A) human CD47 or (B) control protein. Cells were stained with 1 µg/ml anti-CD47 neutralising antibody (Magrolimab).